Neostigmine
- Generic Name
- Neostigmine
- Brand Names
- Bloxiverz, Prevduo, Prostigmin
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N2O2
- CAS Number
- 59-99-4
- Unique Ingredient Identifier
- 3982TWQ96G
Overview
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Background
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Associated Conditions
- Curarization therapy
- Myasthenia Gravis
- Neuromuscular Blockade
- Postoperative Urinary Retention (POUR)
- Acute Colonic Pseudo-Obstruction
- Post-operative intestinal atony
FDA Approved Products
neostigmine methylsulfate
Manufacturer:Civica Inc.
Route:INTRAVENOUS
Strength:0.5 mg in 1 mL
Approved: 2021/05/06
NDC:72572-460
Bloxiverz
Manufacturer:Exela Pharma Sciences, LLC
Route:INTRAVENOUS
Strength:0.5 mg in 1 mL
Approved: 2023/12/31
NDC:51754-1210
Neostigmine Methylsulfate
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:0.5 mg in 1 mL
Approved: 2022/06/30
NDC:63323-413
Bloxiverz
Manufacturer:Exela Pharma Sciences, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2023/12/31
NDC:51754-1220
Neostigmine
Manufacturer:Dr.Reddy's Laboratories Inc
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2021/02/02
NDC:43598-529
Singapore Approved Products
SETISIN INJECTION 2.5 mg/ml
Manufacturer:DUOPHARMA (M) SDN BHD
Form:INJECTION
Strength:2.5 mg/ml
Online:Yes
Approved: 1999/06/26
Approval:SIN10993P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath